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Abstract
Background Whether to perform a renal biopsy for iso-
lated hematuria remains a matter of controversy. We per-
formed renal biopsy in hematuria without overt proteinuria
patients and reported the proportion of glomerulonephritis,
pathological activities, and statistical analysis of indicators
associated with glomerulonephritis.
Methods Among 203 patients who underwent renal
biopsy in Okubo Hospital, Japan, between January 2008
and October 2013, we identified 56 patients who fulfilled
the criteria: (1) urine dipstick examination shows equal to
or greater than ± blood on three or more visits, (2) pro-
teinuria \0.3 g/day (g/g Cr), (3) eGFR ]60 ml/min/
1.73 m2, and (4) no current medication for renal disease.
We investigated biopsy findings and compared the clinical
indicators in the IgA nephropathy (IgAN) and non-IgAN
group.
Results The pathological diagnosis was IgAN in 35 cases
(62 %), thin basement membrane disease (TBMD) in 7
(13 %), minor glomerular abnormality (MGA) in 6 (11 %),
glomerular basement membrane (GBM) abnormality in 5
(9 %), and others in 3 (5 %). The histological grade of
IgAN was I in 90 % and II in 10; 31 % of patients had
some crescentic lesions. Comparisons between the IgAN
and non-IgAN group revealed significant differences in age
of onset (26 ± 13 vs. 34 ± 17 years, p = 0.04), serum
IgA (340 ± 114 vs. 220 ± 101 mg/dl, p\ 0.01), protein-
uria (0.08 [0–0.25] vs. 0 [0–0.23] g/day [g/gCr], p\ 0.01),
and the presence of poikilocytes (40 vs. 10 %, p = 0.02).
Conclusions The proportion of IgAN in hematuria with-
out overt proteinuria was high and the pathological ac-
tivities were variable. Patients with hematuria without
overt proteinuria should continue their medical follow-up
and the best timing of biopsy may be controversial for
these patients who have multiple risk factors of IgAN.
Keywords Hematuria without overt proteinuria  Renal
biopsy  IgA nephropathy
Introduction
Isolated hematuria is a common urinary abnormal
laboratory finding in clinical practice and is defined as
persistent asymptomatic microscopic hematuria in the
absence of hypertension, overt proteinuria, renal insuffi-
ciency, urinary tract infection, or structural abnormality
of the urinary tract [1, 2]. Although isolated hematuria is
sometimes an early sign of glomerulonephritis, no defi-
nite conclusions have been reached regarding the natural
history of patients with isolated hematuria. Whether to
perform a renal biopsy in patients with isolated hema-
turia remains a matter of controversy. Some nephrolo-
gists do not recommend performing a renal biopsy
because diagnosis of a specific renal disease does not
make any difference in terms of either patient manage-
ment or treatment outcome, whereas other nephrologists
recommend a renal biopsy because they think it will
result in a more accurate diagnosis and prognosis [3–5].
In the present study, we performed a renal biopsy in
patients with hematuria without overt proteinuria, and we
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report the proportion of patients with glomerulonephritis,
pathological activities, and the results of statistical ana-
lysis to identify clinical indicators associated with
glomerulonephritis.
Subjects and methods
Study population and entry criteria
Between January 2008 and October 2013, a percutaneous
needle renal biopsy was performed on 203 patients in the
Department of Nephrology of the Okubo Hospital Tokyo
Metropolitan Health and Medical Treatment Corporation.
This study was approved by the research ethics board of
Okubo Hospital and conducted in accordance with the
ethical standards of the Helsinki Declaration. All patients
gave their informed consent to undergo the renal biopsy.
The subjects of this study were the 56 patients who
fulfilled all of the following criteria: (1) urine dipstick
examination shows equal to or greater than ± blood on
three or more visits to our hospital, (2) maximum pro-
teinuria between first visit and renal biopsy\0.3 g/day or
g/g creatinine (Cr), (3) lowest estimated glomerular filtra-
tion rate (eGFR) ]60 ml/min/1.73 m2 at the time of the
renal biopsy; eGFR = 194 9 serum Cr-1.094 9 age-0.287
for males (9 0.739 if female) [6], and (4) no past history of
medication for renal disease.
Evaluations of the renal biopsy specimens
Each renal biopsy specimen was divided into three
parts, one for light microscopy (LM), the second for
immunofluorescence (IF) microscopy, and the third for
electron microscopy (EM). The diagnostic criteria of
the WHO classification of renal disease were used to
make the pathological diagnoses [7]. An EM examina-
tion was performed when the cause of the hematuria
could not be determined on the basis of the LM and IF
findings. We defined mesangial IgA with C3 deposition
as a ‘‘IgA nephropathy (IgAN)’’, only IgA deposition
without C3 composition as a ‘‘IgA deposition’’, absence
of abnormal LM, IF, and EM findings as a ‘‘minor
glomerular abnormality (MGA)’’, and showing the
thinning (^200 nm) of diffuse basement membrane as
a ‘‘thin basement membrane disease (TBMD)’’. Patients
with no IgA lesions but some GBM abnormalities who
did not fulfill the ‘‘TBMD’’ criteria, i.e., lysis and focal
thinning, were diagnosed with a ‘‘glomerular basement
membrane (GBM) abnormality’’. We graded the
pathological activity of IgAN based on the histological
grade (H-grade) classification of the Japanese Society of
Nephrology [8].
Investigation of clinical indicators
We investigated the following clinical indicators: sex, age
at the onset of hematuria (first time when the patient was
told of the presence of hematuria), serum IgA level at the
first visit (mg/dl), interval between the onset and renal
biopsy (year), urinary erythrocyte count per high-power
field (U-RBC) (/HPF), amount of proteinuria (U-prot)
(g/day or g/gCr), serum Cr level at the time of renal biopsy
(mg/dl), eGFR at the time of renal biopsy (ml/min/
1.73 m2), previous gross hematuria based on medical his-
tory, hypertension (blood pressure ]140/90 mmHg or
treatment with an antihypertensive agent), urinary poik-
ilocytes, urinary red blood cell casts, and nut-cracker
phenomenon (difference between the renal vein diameter to
the right and left of the superior mesenteric artery on a
simple CT scan).
Statistical analysis
Results for age at onset, serum IgA levels, and eGFR are
shown as mean ± standard deviation (SD), and the results
for U-RBC, U-prot, and interval from onset to biopsy are
shown as median values (range). Based on the pathological
diagnoses, we divided the patients into an IgAN and a non-
IgAN group. Wilcoxon analysis was used on an ordinal
scale and Fisher’s exact test on nominal scale to compare
the groups. A p value\0.05 was considered to be statis-
tically significant. A receiver operating characteristic
(ROC) analysis was performed. ROC curves are graphic
representations of the relationship between sensitivity and
specificity of a diagnostic parameter and are drawn through
potential points that represent different decision levels.
All statistical analyses were performed using JMP11
statistical package (SAS Institute Inc. Japan); p val-
ues\0.05 were considered to be statistically significant.
Results
The 56 subjects consisted of 32 males and 24 females, and
their mean age at the time of renal biopsy was
29 ± 15 years. The distribution of duration to renal biopsy
is shown in Fig. 1. A renal biopsy was performed on 3
patients to assess them as potential renal transplant donors.
The mean grade of hematuria was U-RBC 10–19/HPF
without overt proteinuria ([0.3 g/day or g/gCr) and renal
insufficiency. The mean serum Cr and eGFR values at the
time of renal biopsy were 0.82 ± 0.09 mg/dl and
92.9 ± 14.9 ml/min/1.73 m2 for males, and
0.62 ± 0.10 mg/dl and 91.1 ± 18.3 ml/min/1.73 m2 for
females, respectively. Their mean serum IgA level was
295 ± 123 mg/dl, and the mean amount of U-prot was
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0.04 (0–0.25) g/day (g/gCr). There were 8 patients (14 %)
with U-prot ]0.15 g/day (g/gCr). There were 18 patients
(33 %) with a past history of gross hematuria, 9 (16 %)
with a history of hypertension, 16 (29 %) with a history of
urinary poikilocytes, and 3 (5 %) with a past history of
urinary red blood cell casts. Abdominal CT was performed
in 22 cases (39 %) and nut-cracker phenomenon was ob-
served in 5 cases (Table 1).
The pathological diagnosis was IgAN in 35 cases
(62 %), TBMD in 7 cases (13 %), MGA in 6 cases (11 %),
GBM abnormality in 5 cases (9 %), and others in 3 cases
(5%; endothelial injury in 1 case and benign nephroscle-
rosis in 2 cases). No EM examination was performed in
two cases (MGA and benign nephrosclerosis).
Glomerular lesions are compared in Table 2. Glomeru-
losclerosis was observed in other diseases as well as IgAN.
Adhesions, crescents, and focal segmental sclerosis (FGS)
lesions were observed only in IgAN. The distribution of H
grade of IgAN was H-grade I in 90 % (10 of I, 2 of Ia, 13
of Ic and 8 of I a/c) and grade II (2 of II c) in the other
10 %. The glomerular lesions in IgAN consisted of adhe-
sions in 40 %, cellular crescents in 9 %, fibrocellular
crescents in 11 %, fibrous crescents in 17 %, FGS lesions
in 6 %, and some form of crescentic lesions in 11 IgAN
patients (31 %).
Table 3 shows the U-RBC and U-prot levels and num-
bers of patients with a previous gross hematuria, compli-
cation by hypertension, presence of urinary poikilocytes,
and history of urinary red blood cell casts in each disease.
While U-RBC counts were almost equal among all
diseases, proteinuria appeared more frequently in patients
with IgAN and MGA than others. Gross hematuria was
observed in most IgAN cases and in some MGA, TBMD,
and GBM abnormality cases. Hypertension was observed
in about 20–30 % of each disease group, but not in any of
the MGA cases. Poikilocytes were observed in 14 cases of
IgAN, 1 case of the GBM abnormality group, and 1 case of
other disease (EM was not performed). Red blood cell casts
were observed in IgAN, TBMD, and others. The nut-
cracker phenomenon was observed in 3 IgAN patients.
Table 4 shows the comparison of the IgAN and non-
IgAN groups in terms of clinical indicators, showing sig-
nificant differences in age at onset (26 ± 13 vs. 34 ± 17,
p = 0.04), serum IgA level (340 ± 114 vs.
220 ± 101 mg/dl, p\ 0.01), U-prot (0.08 vs. 0.00 g/day
or g/gCr, p\ 0.01), and presence of urinary poikilocytes
(40 % vs. 10 %, p = 0.02). We performed ROC analysis to
determine the cutoff point of these parameters for
separating IgAN from non-IgAN. The cutoff point of age at
onset was 27 years (AUC 0.66, sensitivity 0.65, specificity
0.61, positive predictive value 0.74, negative predictive
value 0.52) and serum IgA level was 213 mg/dl (AUC
0.85, sensitivity 0.97, specificity 0.71, positive predictive
value 0.85, negative predictive value 0.94), U-prot was
0.04 mg/dl (AUC 0.74, sensitivity 0.71, specificity 0.81,
positive predictive value 0.93, negative predictive value
0.59).
We also analyzed the prevalence rate of IgAN taking
0.15 g/day (g/gCr) of U-prot as a cutoff point, but there
Fig. 1 Distribution of duration to renal biopsy (years) (n = 56) (n)
Table 1 Baseline characteristics of the study population
n = 56
Gender (male:female) 24:32
Age of onset (years old)a 29 ± 15
Serum IgA (mg/dl)a 295 ± 123
U-RBC (/HPF)b 10–19 (1–4/-[100/)
U-prot (g/day or g/gCr)b 0.04 (0–0.25)
Cr (mg/ml) (male:female)a 0.82 ± 0.09:0.62 ± 0.10
eGFR (ml/min/1.73 m2) (male:female)a 92.9 ± 14.9:91.1 ± 18.3
Duration to renal biopsy (year)b 2 (0–46)
Previous gross hematuriac 18 (33 %)
Hypertensionc 9 (16 %)
Poikilocytec 16 (29 %)
Red blood cell castc 3 (5 %)
Nut-cracker phenomenon 5(IgAN3, MGA2)
Under 22 CT examination performed
U-RBC urinary red blood cells, U-prot urinary protein excretion, Cr
creatinine, eGFR estimated glomerular filtration rate
a mean ± SD
b median (range)
c n (%)
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was no significant difference in U-prot with 0.15 g/day or
more and under (20 vs. 10 %, p = 0.19).
Discussion
In the present study, we made a pathological diagnosis
based on the renal biopsy findings in 56 patients with he-
maturia without overt proteinuria, and the results showed
that they had a variety of renal diseases. The most common
cause was IgAN. The proportion of patients with IgAN was
62 % and with TBMD 13 %. Previous studies have re-
ported the presence of IgAN and TBMD in 10–60 % of
patients with isolated hematuria [5, 9–12]. Since the
prevalence rate of IgAN and TBMD has been reported to
differ according to geographic location because of differ-
ences in the frequency of urinalysis screening, indications
for renal biopsy in patients with isolated hematuria, and
availability of EM from country to country [13, 14], renal
biopsy of patients with hematuria without overt proteinuria
might yield more accurate diagnoses.
Differentiating between renal disease and urological
disease is difficult without performing an invasive ex-
amination, such as renal biopsy or cystoscopy. In some
patients the hematuria spontaneously resolves, but in others
it is later associated with proteinuria, and it is a risk factor
for end-stage renal disease [12, 14–16]. In Japan, IgAN is
the most common form of glomerulonephritis as a cause of
end-stage renal disease. The renal prognosis of having
hematuria without overt proteinuria may be improved by
early diagnosis and early treatment. In addition, especially
in Japan, there are many opportunities to identify chance
hematuria during school health checkups and regular
checkups at work; it is meaningful to study about the
timing of renal biopsy.
Clinical indicators such as younger age, high serum IgA
level, proteinuria, and presence of urinary poikilocytes may
be useful in differentiating IgAN from non-IgAN. Our






















TBMD (7) 16 ± 7 0 0 0 0 0 3 (43)b
18 ± 14.1c
MGA (6) 26 ± 12 0 0 0 0 0 0
GBM
abnormality (5)
14 ± 5 0 0 0 0 0 1 (20)b 14c
Others (3) 27 ± 12 0 0 0 0 0 3 (100)b
17.3 ± 16.3c
Rate of crescents in IgAN is 11/35 (31 %)
IgAN IgA nephropathy, TBMD thin basement membrane disease, MGA minor glomerular abnormality, GBM glomerular basement membrane
a Mean ± SD
b n (%)
c Rate of lesion in positive patients [lesion/total glomeruli, mean ± SD (%)]









Poikilocyteb Red blood cell
castb
IgAN (n = 35) 20 (0–100) 0.08 (0–0.3) 14 (40) 7 (20) 14 (40) 1 (3)
TBMD (n = 7) 5 (5–30) 0 1 (14) 1 (14) 0 1 (14)
MGA (n = 6) 20 (0–100) 0.01 (0–0.23) 2 (33) 0 0 0
GBM abnormality
(n = 5)
20 (1–100) 0.00 (0–0.1) 1 (20) 1 (20) 1 (20) 0
Others (n = 3) 10 (1–30) 0.00 (0–0.17) 0 1 (33)c 1 (33)c 1 (33)
a Median (range)
b n (%)
c Same person (not performed EM)
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analysis showed that the best cutoff point of age at onset
was 27 years and it did not conflict with a report that
pathological abnormality was the most common (69.2 %)
in 20–30 years old patients with isolated hematuria [18].
The best cutoff point for IgA level was 213 mg/dl,
which was lower than the clinical guidelines for IgAN in
Japan [19]. It described that greater than 315 mg/dl is a
frequent finding in adults with IgAN. Tomino set the cutoff
point at 315 mg/dl and reported that the incidence of more
than 315 mg/dl in IgAN is significantly higher than that in
non-IgAN [20]. In our study, the cutoff point of 213 mg/dl
has high AUC and sensitivity and negative predictive
value. It shows that the possibility of IgAN is low when
IgA is less than 213 mg/dl, however, it cannot be unex-
cludable when it is less than 315 mg/dl. There are few
reports about serum IgA of IgAN and this analysis is
useful.
The best cutoff point of U-prot was 0.04 mg/dl, it was
also lower than expected. It may be caused by limiting
population to patients with U-prot\0.3 g/day (g/g Cr) in
this study. We limited the population with U-prot
\0.3 g/day (g/gCr) as ‘‘patients of hematuria without
overt proteinuria’’, according to the ‘‘Guideline of Renal
Biopsy’’ by Japan Society of Nephrology 2005 [21]. Re-
cent change in guideline [22, 23] has redefined the cutoff
point to ]0.15 g/day (g/gCr) as positive for proteinuria.
We also analyzed the prevalence rate of IgAN with
0.15 g/day or more and under, and there was no sig-
nificant difference between two groups. It is suggested
that some of the non-IgAN patients show mild proteinuria
around 0.02 g/day. Based on its sensitivity and specificity,
the cutoff point of U-prot 0.04 mg/dl was not a good
parameter for separating IgAN from non-IgAN. And
based on its high positive and low negative predictive
value, the positive proteinuria is helpful for diagnosis of
IgAN while the negative proteinuria cannot deny it. We
should be careful while making a diagnosis based on the
amount of proteinuria alone.
Poikilocytes appeared more in IgAN than in non-IgAN,
but the proportion was less than 50 % in IgAN and some
other diseases were also positive. Poikilocytes cannot be
identified if urine is hypotonic [24] and it is identified in
patients with TBMD [25], suggesting the difficulty in
making a differential diagnosis based on these indicators
alone.
In addition, the presence of the nut-cracker phenomenon
is not useful for the exclusive diagnosis of IgAN, because
there were 3 patients with nut-cracker phenomenon co-
morbid with IgAN. After more than 4–5 years of persistent
hematuria, a renal biopsy should be performed because
hematuria in persons with normal renal tissue resolves in
about 4–5 years [9, 10]. However, we cannot determine the
significant differences in intervals from onset to renal
biopsy between the IgAN and non-IgAN groups.
The pathological activities of IgAN were variable. Some
IgAN patients have minor proliferative mesangial expan-
sion without acute and chronic lesion [H-gradeIA(-)C(-),
30 %], while others have H-gradeIIA/C (10 %) with both
lesions. Glomerulosclerosis may not be a pathognomonic
lesion of IgAN, because its presence has been identified in
other diseases. Unexpectedly, when the total glomeruli
numbers were small, a crescent as an acute lesion was
identified only in IgAN and its proportion was no less than
30 % of all patients. All types of crescents including cel-
lular, fibrocellular, and fibrous were observed. Adhesion is
not determined as active lesion at H grade; it was identified
in 40 % of the IgAN patients. This means that there are
both old and new findings of glomerulonephritis with
capillaritis without overt proteinuria and renal dysfunction,
and spot urinary findings only cannot be used to estimate
their activities. Therefore, it is difficult to diagnose and
assess activity on the basis of glomerulonephritis according
Table 4 Comparison of clinical
indicators in IgAN and non-
IgAN group
* p value\0.05 was considered
statistically significant
a Mean ± SD
b Median (range)
c n (%)
IgAN (n = 35) Non-IgAN (n = 21) p
Gender (male:female) 17:18 7:14 0.26
Age of onset (years old)a 26 ± 13 34 ± 17 0.04*
Serum IgA (mg/dl)a 340 ± 114 220 ± 101 \0.01*
U-RBC (/HPF)b 20–29/(1–4/- ]100/) 10–19/(1–4/- ]100/) 0.87
U-prot (g/day or g/gCr)b 0.08 (0–0.25) 0.00 (0–0.23) \0.01*
Serum Cr (mg/ml)a 0.72 ± 0.15 0.68 ± 0.12 0.27
Duration to renal biopsy (year)b 2 (0–23) 1 (0–46) 0.42
eGFR (ml/min/1.73 m2)a 94.3 ± 18.3 87.9 ± 13.4 0.15
Previous gross hematuriac 14 (40) 4 (19) 0.10
Hypertensionc 7 (20) 2 (10) 0.30
Poikilocytec 14 (40) 2 (10) 0.02*
Red blood cell castc 1 (3) 2 (10) 0.28
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to only the one clinical indicator in patients with hematuria
without overt proteinuria.
According to the present guidelines for IgAN in Japan,
there is no necessity for a renal biopsy in patients with
hematuria without overt proteinuria because the prognosis
seems to be good. Renal biopsy has some complications,
and a nephrologist should be careful in deciding to inves-
tigate by biopsy. However, Feng reported that among
prognoses of pediatrics with isolated hematuria (U-prot
\0.1 g/day), 6 % had adverse renal events during their
follow-up period of 10 years [26]. Lee also reported that
also even clinically early IgAN patients (eGFR ]60 ml/
min/1.73 m2, U-prot\0.5 g/day) can show a progressive
disease trajectory, and 15 % progressed to ESRD during
30 years [27]. Also, Ieiri reported that the long duration of
IgAN led to lower clinical remission [17].
Therefore, clinical nephrologists should carefully ob-
serve patients with hematuria without overt proteinuria and
not let them drop out of their medical follow-up. They
should find out the best timing for biopsy and investigation
of treatment. Especially, for those patients who have
multiple indicators, such as younger age, higher serum IgA
level, positive poikilocytes, or some social problems such
as donor and high risk of dropout, it may be useful to
decide on the therapeutic principle.
The present study had several limitations. First, the
sample size was small and had a selection bias for subjects.
Usually, routine criteria of renal biopsy in our hospital is
sustained proteinuria (?)–(2?) or 0.3–0.5 g/day (g/gCr)
according to the guideline of renal biopsy [18]. With the
existence of special IgAN outpatient division in our hos-
pital, we accepted some patients who did not fulfill the
criteria came and wanted to receive a thorough examina-
tion to determine the presence or absence of IgAN. In
addition, among the subjects there were three candidates
for renal transplant donor and had large selection bias. We
obtained informed consent from all patients before the
biopsy after explaining the possibility of TBMD or nut-
cracker phenomenon and spontaneous remission in IgAN.
Many patients desire a definitive diagnosis that enables
them to decide on future plans: to pass examinations at
school age and to find employment at working age. Women
in the reproductive age may get married or pregnant after
identifying the cause of hematuria. Nephrologists should
consider the indication of renal biopsy on the basis of the
patient’s social background as well as their medical data.
Second, all IgAN patients in this study received tonsil-
lectomy and/or steroid and were led to complete. Because
they all wanted to cure IgAN and they had a common
reason for receiving the biopsy among them. However, it is
difficult for us to observe their natural history.
As a future project, it is necessary to perform a longi-
tudinal study to investigate the long-term outcome in these
IgAN patients without overt proteinuria for 10 years or
more. It may give us a new suggestion of the best timing
for renal biopsy.
Conclusions
The results of this study showed that a high proportion of
the patients with hematuria without overt proteinuria had
IgAN. It is difficult to diagnose glomerulonephritis or
assess its activity on the basis of only one clinical indicator.
It may be useful to extend indications of renal biopsy by
the comprehensive consideration of medical data and social
backgrounds.
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